EQ
Equillium
Stock NASDAQ – Stock Market Prices, News & Analysis
Equillium Inc est une société biotechnologique développant des traitements pour les maladies auto-immunes et inflammatoires.
Equillium
EQ
Equillium Inc est une société biotechnologique développant des traitements pour les maladies auto-immunes et inflammatoires.
Price history of Equillium
Price history of Equillium
Performance & Momentum
Equillium progresses with EQ504 ulcerative colitis trial
Equillium Inc (NASDAQ: EQ) is preparing to launch the Phase 1 trial of its EQ504 treatment targeting ulcerative colitis, scheduled for mid-2026. The company recently held several events with field experts to highlight the clinical potential of this AhR receptor modulator in treating inflammatory bowel diseases. Additionally, Equillium has secured $30 million in funding, ensuring operations through 2027, and is strengthening its team with stock bonuses for new hires. These developments signal positive prospects for the biotech, likely to attract mid-term investor interest.
Similar stocks to Equillium
Recent News
Equillium
Equillium Secures $50M Funding, Strengthens Pipeline
1 month agoEquillium Inc (NASDAQ: EQ) has closed a financing round of up to $50 million, with an initial $30 million tranche providing financial visibility through 2027. The biotech highlights its candidate EQ504, an oral Aryl Hydrocarbon Receptor (AhR) modulator targeting ulcerative colitis, with a Phase 1 launch planned for mid-2026. Meanwhile, the company is boosting communication through multiple investor conferences and key events, reflecting an active strategy to enhance its position in the growing autoimmune disease market.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
